This is consistent with previous studies of IGF2BP2 in cancers, including colorectal cancer (Wang et al., 2019), gastrointestinal cancer (Zhou et al., 2017), endometrial cancer (Hiramatsu et al., 2016), pancreas cancer (Xu et al., 2019), breast cancer (McMullen et al., 2018), and hepatic carcinoma. Here, IGF2BP2 is linked to endometrial cancer.